SynBio

For the field of science, see Synthetic biology.
SynBio
IndustryBiotech Research and Pharmaceuticals
FoundedAugust 2011 (2011-08)
HeadquartersMoscow, Russia
OwnerRusnano, HSCI, FDS Pharma, Dmitry Genkin, Cryonix, and Pharmsynthez
Websitewww.synbio-pharma.com

SynBio is a long-term project started in 2011 with the goal of creating innovative medicines, including what are known as Biobetters. This project is a collaborative effort of several Russian and international pharmaceutical companies. The largest private participant of SynBio is the Human Stem Cells Institute (HSCI), a leading Russian biotech company, and Rusnano is a key investor.[1] The project is a significant example of international cooperation between researchers in Russia, England, and Germany. Special project company SynBio LLC is headquartered in Moscow.[2]

Currently, SynBio LLC is developing nine drugs based on three biotechnology platforms (Histone, PolyXen and Gemacell) for the treatment of liver disease, cardiovascular disease, acute leukemia, growth hormone deficiency and diabetes mellitus.[3][4]

The SynBio project also entails the creation of modern production facilities. These facilities will be dedicated to the manufacturing of the company's pharmaceutical substances and market-ready medicines once they have successfully undergone clinical testing.[5]

Research and Development Centers

  • Xenetic Biosciences (London, Great Britain) is a leading biopharmaceutical company operating from the UK that develops high-value, differentiated pharmaceutical products in the fields of protein drugs, vaccines and anti-cancer drugs.[6]
  • SymBioTec GmbH (Saarbrücken, Germany) is a company working to develop next generation medicines for the treatment of cancer and infectious diseases. SymBioTec has a state-of-the-art biotech laboratory equipped for proteomics, cell and molecular biology as well as biotechnology.[7]
  • HSCI (Moscow, Russia) is one of the leading biotech companies of Russia that is engaged in development of cell- and gene-based technologies with promising medical applications.[8]

References

  1. ^ "Russian firms set upset up $113 million biotech venture". Pharma Times Online. August 9, 2011.
  2. ^ "About Us". SynBio.
  3. ^ "Russian Firms Establish Joint Biotech Venture". Pharmaceutical-Technology. 10 August 2011.
  4. ^ "Russia biotech: Innovation drive". The Economist Intelligence Unit. August 16, 2011.
  5. ^ "В Ленобласти будут производить лекарства против болезни Альцгеймера". Делового Петербурга. August 5, 2011.
  6. ^ "Xenetic Biosciences".
  7. ^ "Symbiotech".
  8. ^ "HSCI".

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.